Stifel Nicolaus analyst Ingrid Rico maintained a Buy rating on B2Gold (BTG – Research Report) today and set a price target of C$6.50. The company’s shares closed last Friday at $2.88.

BTG Pactual initiated coverage of Arcos Dorados (ARCO) with a Buy rating and $10.50 price target Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst ...

In this article, we are going to take a look at where B2Gold Corp. (NYSEAMERICAN:BTG) stands against other cheap Canadian stocks to buy according to analysts. In January, RBC Global Asset ...

In this article, we are going to take a look at where B2Gold Corp. (NYSE:BTG) stands against other best gold penny stocks to buy now. The global precious metals market is influenced by economic ...

Sun Pharma has agreed to purchase the Massachusetts biotech for an upfront value of $355 million, or $4.10 per share, the companies said Sunday. With Unloxcyt, an FDA-approved PD-L1 therapy for ...

In this article, we are going to take a look at where B2Gold Corp. (NYSEAMERICAN:BTG) stands against other best penny stocks to buy according to billionaires. On February 14, Morningstar released ...

March 10 (Reuters) - India's Sun Pharmaceutical Industries (SUN.NS), opens new tab said on Monday it will acquire Checkpoint Therapeutics (CKPT.O), opens new tab, a U.S.-based immunotherapy and ...

My wife and I would both be dead, but for what many derisively call “Big Pharma.” My wife has a rare, genetic form of stage four lung cancer for which there is no cure. Her lungs are filled ...

It demands significant resources that are often expensive and inaccessible to biotechnology and pharmaceutical companies of all sizes. Federal regulations like the Current Good Manufacturing ...

Apr. 1, 2025 — A team has developed a new way to quickly find personalized treatments for young cancer patients, by growing their tumors in chicken eggs and analyzing their proteins. The team ...

In his March 17 op-ed, “We should stop acting as if Big Pharma is the big villain in American health care,” Erick Erickson writes, “The government cannot provide clarity or direction for ...